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Background: B cell depleting therapy is widely used for lymphoproliferative diseases and immune-mediated
disorders, including mucous membrane pemphigoid. The latter is an autoimmune blistering disease affecting
predominantly the mucosae potentially associated with devastating complications.
Methods: A 71-year-old patient with severe mucous membrane pemphigoid involving ocular, oral pharyngeal and
laryngeal involvement is described. To control the disease, the patient was given rituximab therapy in combination
with oral corticosteroids. He subsequently experienced an epithelial herpes simplex virus keratitis in one eye and
3 months later in his fellow eye. Topical treatment with ganciclovir resulted in prompt recovery.
Results: For the first time, a correlation between rituximab and bilateral epithelial herpes simplex virus keratitis is
described.
Conclusions: Although rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the
risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.
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Rituximab is a B cell depleting anti-CD20 monoclonal
antibody that is increasingly used to treat autoimmune
disorders and B cell non-Hodgkin lymphoma. It has be-
come an important therapeutic option for the treatment
of refractory mucous membrane pemphigoid [1, 2]. As
with other immunosuppressive agents, there is the risk of
opportunistic infections or reactivations, including hepa-
titis B virus and herpes viruses (HSV) [3–5]. Here, we re-
port a potential association between rituximab and de
novo corneal infection with HSV.Clinical case
A 71-year-old male patient had a 3-year history of mucous
membrane pemphigoid. He first presented with oral ulcer-
ations, cicatrising conjunctivitis as well as cutaneous blis-
ters. He was initially treated with prednisone 1 mg/kg/* Correspondence: wolfgang.bernauer@hin.com
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the Creative Commons license, and indicate if24 h and azathioprine 2 × 100 mg/24 h with subsequently
progressive tapering of the oral corticosteroids. Azathio-
prine was stopped 18 months after the therapy start.
Nevertheless, 2 years after initial diagnosis, he relapsed
with severe oral and larynx involvement with dysphagia
and respiratory distress. The latter required a tracheotomy
with reintroduction of the immunosuppressive treatment.
Prednisone 1 mg/kg/24 h and again azathioprine 2 ×
50 mg/24 h were given over a period of 3 months. This
was beneficial with regard to the skin lesions but had only
little effect on the severe oral and laryngeal inflammation.
Therefore, the patient received rituximab (MabThera),
two times 1000 mg 2 weeks apart. Six weeks after the first
infusion of rituximab, there was a significant regression of
the oral lesions, but new ocular symptoms developed. The
patient complained of foreign body sensation and of
blurred vision in his right eye. Vision in this right pseudo-
phacic eye had dropped to 0.5, and a new epithelial defect
was seen at slit lamp examination (Fig. 1). The changes of
the corneal epithelium were suggestive of a dendritic epi-
thelial ulceration as seen in HSV keratitis. An impressionis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 A new epithelial defect was seen at slit lamp examination
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to confirm the diagnosis of HSV epithelial keratitis. Top-
ical treatment with ganciclovir gel 1.5 mg/g (Virgan) 4×/
24 h was started. Seven days later, the corneal surface re-
covered completely and without any opacification. A
maintenance therapy with ganciclovir gel 1.5 mg/g 1×/
24 h was started. Noteworthy, to that date, there was no
previous history of muco-cutaneous HSV disease. The
immunosuppressive therapy was tapered to 40 mg pred-
nisone/24 h and azathioprine 50 mg/24 h. Four months
after the first infusion with rituximab, the patient devel-
oped new ocular symptoms in his left eye. He presented
with an increasing foreign body sensation, vision 0.1 due a
dense cataract and an epithelial keratitis (Fig. 2a, b). As
for the right eye, HSV epithelial keratitis was confirmed.
Treatment with ganciclovir 1.5 mg/g 4×/24 h resulted in a
rapid response with resolution of the keratitis within
10 days. The patient was given a maintenance therapyFig. 2 a–d A dense cataract and an epithelial keratitiswith ganciclovir gel 1.5 mg/g 1×/24 h. There were no fur-
ther episodes of HSV keratitis during the subsequent
12-month follow-up.
Diagnostics and intervention
The clinical diagnosis of mucous membrane pemphigoid
was confirmed based on the characteristic clinical features,
consistent light microscopy findings and positive immuno-
pathological findings. The direct immunofluorescence mi-
croscopy studies showed linear IgG and C3 deposits along
the epidermal basement membrane. By indirect immuno-
fluorescence microscopy using saline-split normal human
skin as substrate, the patient had circulating autoantibodies
reacting against the epidermal side of the split, while the
ELISA-BP180 (MBL International, Japan) was positive
(49.4 U/mL; normal value < 9 U/L). The lymphocyte count
was reduced to 0.8 × 109/L 6 months after the intensifica-
tion of the immunosuppressive therapy, i.e. 2 months after
the onset of HSV keratitis in the right eye.
For the diagnosis of the ocular surface changes, an
impression cytology technique was used as described
elsewhere (Fig. 2c) [6]. The impressions were processed,
using monoclonal antibodies to assess the presence of
HSV (fluorescein isothiocyanate-labelled mouse mono-
clonal antibodies to HSV-1 antigen, Evans Blue
counterstain; MicroTrak HSV-1 Culture Identification/
Typing Reagent, Trinity Biotech). The impressions were
tested positive for HSV-1 in both eyes (Fig. 2d). Ganci-
clovir gel 1.5 mg/g was applied topically 4×/24 h to
treat the superficial HSV keratitis for 10 days. Once the
epithelial changes had resolved, a maintenance therapy
with ganciclovir gel 1×/24 h was established. No topical
steroids were applied.
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This is the first report on bilateral epithelial HSV-1 kera-
titis in a patient with progressive severe mucous mem-
brane pemphigoid. The keratitis first developed in one
eye, and 3 months later in the fellow eye. HSV keratitis
is usually regarded as a recurrence of a primary infection
during childhood. In most cases, it presents as an unilat-
eral condition [7, 8]. A compromised immune system,
however, is a well-recognised risk factor for bilateral
HSV keratitis [7, 8]. Therefore, patients with auto-
immune disorders are at risk while on anti-inflammatory
medication. Various immunosuppressive drugs have
been linked to the reactivation of viral infections. They
have also been reported for rituximab, including reacti-
vations of polyomaviruses, hepatitis B virus and viruses
of the herpes group (cytomegalovirus and Epstein-Barr
virus) [3, 4]. However, there is no previous report on re-
activation of HSV-1 keratitis or de novo corneal infec-
tion with HSV-1.
The sequence of therapy change in our patient
strongly suggests a causal relation between rituximab
use and the development of a first episode of HSV-1
keratitis in one eye, and later in the fellow eye. It is also
conceivable that the previous immunosuppressive regi-
men with steroids and azathioprine has put our patient
at additional risk for herpes infection.
Special clinical and laboratory monitoring of patients
on immunosuppressive medications including rituximab,
a highly effective biologic agent, is mandatory to exclude
the development for severe infectious complications,
such as in our patient.
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